30925-62-3

Basic information

• Product Name: 2',4',4-TRIMETHOXYCHALCONE
• Synonyms: TRIMETHOXY-4,2',4'-CHALCONE;2',4',4-TRIMETHOXYCHALCONE;(2E)-1-(2,4-Dimethoxyphenyl)-3-(4-methoxyphenyl)-2-propen-1-one;(E)-2',4,4'-Trimethoxychalcone
• CAS NO: 30925-62-3
• Molecular Formula: C₁₈H₁₈O₄
• Molecular Weight: 298.33
• Mol File: 30925-62-3.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2',4',4-TRIMETHOXYCHALCONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2',4',4-TRIMETHOXYCHALCONE(30925-62-3)
• EPA Substance Registry System: 2',4',4-TRIMETHOXYCHALCONE(30925-62-3)

Safety Data

• Hazardous Substances Data: 30925-62-3(Hazardous Substances Data)

Upstream product

• 123-11-5 4-methoxy-benzaldehyde 
• 829-20-9 2',4'-dimethoxyacetophenone 
• 961-29-5 isoliquirtigenin 
• 74-88-4 methyl iodide 
• 13351-10-5 2',4'-dihydroxy-4-methoxychalcone 
• 51828-10-5 2'-methoxyisoliquiritigenin 
• 696-62-8 para-iodoanisole 
• 67756-04-1 1-(2,4-dimethoxy-phenyl)-prop-2-en-1-one 
• 151-10-0 1,3-Dimethoxybenzene 
• 637-69-4 4-Methoxystyrene 
• 20469-63-0 1-iodo-2,4-dimethoxybenzene 
• 82102-37-2 9-methyl-9H-fluorene-9-carbonyl chloride 
• 943-89-5 (E)-3-(4-methoxyphenyl)acrylic acid 
• 3179-10-0 (E)-1-methoxy-4-(2-nitrovinyl)benzene 

Downstream Products

• 40321-75-3 αβ-epoxy-2',4,4'-trimethoxydihydrochalcone 
• 93903-83-4 1-(2,4-dimethoxyphenyl)-3-(4-methoxyphenyl)propan-1-one 
• 30251-89-9 2',4,4'-Trimethoxy-3-nitro-chalcon 
• 30071-40-0 2',4,4'-Trimethoxy-3,5'-dinitro-chalcon 
• 740861-93-2 5-(2,4-dimethoxy-phenyl)-3-(4-methoxy-phenyl)-5-oxo-2-(4-oxo-4,5-dihydro-thiazol-2-yl)-pentanenitrile 
• 223389-76-2 4-(4-methoxyphenyl)-3,5-dimethyl-1,7-diphenyl-4,7-dihydro-1H-pyrano[2,3-c:6,5-c']dipyrazole 
• 740861-78-3 4-[3-(2,4-dimethoxy-phenyl)-1-(4-methoxy-phenyl)-3-oxo-propyl]-2,5-diphenyl-2,4-dihydro-pyrazol-3-one 
• 740861-74-9 4-(4-methoxy-phenyl)-1,3,5,7-tetraphenyl-4,7-dihydro-1H-pyrano[2,3-c;6,5-c']dipyrazole 
• 51813-59-3 2,5,2',5'-tetraphenyl-1,2,1',2'-tetrahydro-4,4'-(4-methoxy-phenylmethanediyl)-bis-pyrazol-3-one 
• 75436-96-3 5-(2,4-dimethoxy-phenyl)-3-(4-methoxy-phenyl)-5-oxo-valeric acid 
• 88689-02-5 5,5'-dimethyl-2,2'-diphenyl-1,2,1',2'-tetrahydro-4,4'-(4-methoxy-phenylmethanediyl)-bis-pyrazol-3-one 
• 740861-94-3 2-amino-6-(2,4-dimethoxyphenyl)-4-(4-methoxyphenyl)-3-(4-oxothiazolidin-2-yl)pyridine 

Relevant articles and documents

Application of human PCID2 protein in preparation or screening of anti-tumor drugs and compound with anti-tumor activity

The invention belongs to the technical field of biotechnology and gene therapy, and particularly relates to application of human PCID2 protein in preparation or screening of anti-tumor drugs and an anti-tumor compound. It is found that the PCID2 gene promotes tumor cell proliferation and regulates the cell cycle, is a key molecule for regulating tumor generation and development, and can be used as a target protein for preparing or screening anti-tumor drugs; meanwhile, human PCID2 protein is used as target protein, a class of PCID2 protein targeting antitumor compounds are screened out through a molecular docking technology, and the compounds can significantly inhibit tumor cell proliferation and promote tumor cell apoptosis.

The synthesis of chalcones as anticancer prodrugs and their bioactivation in CYP1 expressing breast cancer cells

Background: Although the expression levels of many P450s differ between tumour and corresponding normal tissue, CYP1B1 is one of the few CYP subfamilies which is significantly and consistently overexpressed in tumours. CYP1B1 has been shown to be active within tumours and is capable of metabolising a structurally diverse range of anticancer drugs. Because of this, and its role in the activation of procarcinogens, CYP1B1 is seen as an important target for anticancer drug development. Objective: To synthesise a series of chalcone derivatives based on the chemopreventative agent DMU-135 and investigate their antiproliferative activities in human breast cancer cell lines which express CYP1B1 and CYP1A1. Method: A series of chalcones were synthesised in yields of 43-94% using the Claisen-Schmidt condensation reaction. These were screened using a MTT assay against a panel of breast cancer cell lines which have been characterised for CYP1 expression. Result: A number of derivatives showed promising antiproliferative activities in human breast cancer cell lines which express CYP1B1 and CYP1A1, while showing significantly lower toxicity towards a non-tumour breast cell line with no CYP expression. Experiments using the CYP1 inhibitors acacetin and α-naphthoflavone provided supporting evidence for the involvement of CYP1 enzymes in the bioactivation of these compounds. Conclusion: Chalcones show promise as anticancer agents with evidence suggesting that CYP1 activation of these compounds may be involved.

Total synthesis and assignment of the absolute stereochemistry of xanthoangelol J: Development of a highly efficient method for Claisen-Schmidt condensation Dedicated to Late (Dr.) Jadab C. Sarma on his 55th birthday on first May 2013

The first total synthesis of cancer chemopreventive terpenyl hydroxychalcone xanthoangelol J isolated from Angelica keiskei was accomplished with asymmetric epoxidation, aromatic C-alkylation and Claisen-Schmidt condensation via enol mode as key steps. The crucial Claisen-Schmidt condensation has been accomplished by a novel green method using KHSO 4-SiO2 as a recyclable catalyst under microwave activation. The absolute configuration of the molecule was also determined.